Amit, Tamar

Iron dysregulation in Alzheimer's disease: Multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents

Mandel, S., Amit, T., Bar-Am, O., & Youdim, M. B. H. (2007) · Progress in Neurobiology

Alzheimer's disease research and treatmentsMedicinal Plants and Neuroprotection

Cited by 164

Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives

Mandel, S., Weinreb, O., Amit, T., & Youdim, M. B. H. (2005) · Brain Research Reviews

Parkinson's Disease Mechanisms and TreatmentsNeuroprotection in Cerebral Ischemia

Cited by 157

Therapeutic targets and potential of the novel brain‐ permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease1

Avramovich‐Tirosh, Y., Amit, T., Bar‐Am, O., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2007) · Journal of Neurochemistry

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Cited by 130

Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators

Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H., & Mandel, S. (2008) · The FASEB Journal

Alzheimer's disease research and treatmentsIron Metabolism and Disorders

Cited by 126

M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease

Gal, S., Fridkin, M., Amit, T., Zheng, H., & Youdim, M. B. H. (2006) · Parkinson’s Disease and Related Disorders

Parkinson's Disease Mechanisms and TreatmentsCholinesterase and Neurodegenerative Diseases

Cited by 58